Lazertinib, Gefitinib-ratiopharm 250 mg Filmtabletten clinical trials

A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study looks at a new drug, lazertinib, for people with a type of advanced lung cancer. It compares lazertinib to a standard drug, gefitinib, to see which works better at stopping the cancer from growing and if it's safe.